COMMUNICATION
DOI: 10.1002/chem.201302665
a-Isocupreine, an Enantiocomplementary Catalyst of b-Isocupreidine
Yoshito Nakamoto, Fumiya Urabe, Keisuke Takahashi, Jun Ishihara, and
Susumi Hatakeyama*[a]
The Morita–Baylis–Hillman (MBH) reaction including
the aza-version is an atom-economic, efficient carbon–
carbon bond-forming reaction. Due to the utility of highly
functionalized products in synthesis, there has been much in-
terest in the asymmetric version of the MBH reaction.[1] In
1999, we developed a highly enantioselective asymmetric
MBH reaction of aldehydes[2] by use of b-isocupreidine (b-
ICD)[3] as a chiral Lewis base catalyst and 1,1,1,3,3,3-hexa-
fluoroisopropyl acrylate (HFIPA) as an activated alkene
(Scheme 1). In addition, we have demonstrated the synthetic
skeletal rearrangement to give a-isoquinine (a-IQN) (1) in
89% yield. Thereafter, Olah et al. reported that CF3SO3H
also effectively promoted this rearrangement at 508C to
produce 1 in 70% yield.[9] The NOESY spectrum and X-ray
crystallography demonstrated that compound 1 vastly favors
an anti conformation with the 6’-methoxyquinoline moiety
in a horizontal position.[8,9] Given this structural feature, the
demethylated compound 2 is expected to serve as a pseu-
doenantiomer of b-ICD. We report herein the preparation
of a-isocupreine (a-ICPN) (2), a new enantiocomplementa-
ry catalyst of b-ICD, and its catalytic ability.
a-ICPN 2 was first prepared from quinine in 50% yield
by CF3SO3H-promoted rearrangement following Olahꢀs pro-
cedure[9] and demethylation[10] of the rearranged product 1
by using sodium dodecane-1-thiolate at 1308C in DMF
(Scheme 1). During this examination, we found that the first
CF3SO3H treatment directly produced 2 in 19% yield to-
gether with 1 (59%) although the production of 2 had not
been reported in the literature[9] (Table 1, entry 1 and
Scheme 1. b-ICD-HFIPA method.
Table 1. One-step preparation of a-isocupreine from quinine.
utility of this reaction by the syntheses of biologically intri-
guing natural products.[4] This b-ICD-HFIPA method has re-
markable advantages due to the high enantionselectivity,
broad applicability, and availability of both b-ICD and
HFIPA.[2c,5] However, one serious drawback is that this
method cannot be applied to the synthesis of the products
with opposite absolute configuration because the required
enantiomer of b-ICD is not easily available.[6] As one solu-
tion to this problem, we successfully synthesized two effec-
tive enantiocomplementary catalysts of b-ICD from qui-
nine.[7] Nevertheless, since their syntheses required the
lengthy transformations, we still need to develop another
catalyst that is easily available and shows high and opposite
enantioselectivity to that of b-ICD.
Entry
CF3SO3H [equiv]
Conditions
Yield [%][a]
1
2
1[b]
2[c]
3
4
5
275
75
28
28
28
11
508C, 6 h
RT, 24 h
508C, 72 h
508C, 24 h; 808C, 15 h
808C, 24 h
59
64
13
0
0
12
19
0
72
90
65
53
6
508C, 24 h; 808C, 15 h
[a] Isolated yield. [b] Conditions reported by Olah et al. [c] Quinine was
recovered in 30% yield.
Scheme 2). This finding allowed us to investigate the one-
step synthesis of 2 from quinine by using CF3SO3H under
various conditions. Surprisingly, the rearrangement was
found to take place even at room temperature to give 1 in
moderate yield although the reaction did not complete
within 1 day (entry 2). However, when the reaction was con-
ducted at 508C for a longer reaction time, 2 became the
major product (entry 3). Among the conditions examined,
those listed in entry 4 turned out to be optimum for the
preparation of 2. Thus, when quinine was heated in
28 equivalents of CF3SO3H at 508C for 24 h and then at
808C for 15 h, the rearrangement accompanied by demethy-
lation took place cleanly to give 2 in 90% yield. It is impor-
tant to note that under conditions in which quinine was
In 2002, Jacquesy et al. disclosed a novel rearrangement
of quinine in superacid.[8] They found that exposure of qui-
nine hydrochloride to HF-SbF5 at À308C caused a unique
[a] Y. Nakamoto, F. Urabe, Dr. K. Takahashi, Dr. J. Ishihara,
Prof. Dr. S. Hatakeyama
Graduate School of Biomedical Sciences
Nagasaki University
1-14 Bunkyo-machi, Nagasaki 852-8521 (Japan)
Supporting information for this article is available on the WWW
Chem. Eur. J. 2013, 19, 12653 – 12656
ꢁ 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
12653